ISMRM 23rd Annual Meeting & Exhibition • 30 May - 05 June 2015 • Toronto, Ontario, Canada
Study Group Session • MR in Drug Research

Day: Tuesday, 2 June 2015
Time: 10:00-12:00
Room: Reception Hall 104 BCD
Study Group Committee:
Chair, Philip S. Murphy, Ph.D.; Chair-Elect, Geoffrey J. M. Parker, Ph.D.; Program Director, Detlef Stiller, Ph.D.;
Secretary, Alexandre J. Coimbra, Ph.D.; Past Chair, Michael V. Knopp, M.D., Ph.D.
PROGRAM
     
10:00 Welcome & Business Meeting Alexandre J. Coimbra, Ph.D.
    Genentech, Inc., USA
     
10:05 Setting the Scene - Drug Development Challenges Philip S. Murphy, Ph.D.
    GlaxoSmithKline, United Kingdom
     
10:10 MR as a Platform to Study Drug Safety Paul D. Hockings, Ph.D.
    Antaros Medical, Sweden
     
10:30 Translational Challenges with MR - Member Survey Results Detlef Stiller, Ph.D.
  & Discussion Boehringer Ingelheim Pharma Gmbh & CO, Germany
     
10:50 Opportunities for MRI in Experimental Medicine Philip S. Murphy, Ph.D.
    GlaxoSmithKline, United Kingdom
     
11:10 Straight to the Clinic: A Practical Approach to Quantitative  Mark D. Pagel, Ph.D.
  DCE-MRI University of Arizona, USA
     
11:30 Challenges in MR Image Analysis Brandon J. Whitcher, Ph.D.
    GlaxoSmithKline, Clinical Imaging Centre, United Kingdom
     
11:50 Wrap-Up Geoffrey J. M. Parker, Ph.D.
    University of Manchester, United Kingdom
     
12:00 Adjournment